Sign in
Taking people in United StatesPhase 1/2

Gene therapy NVC-001 for dilated cardiomyopathy caused by LMNA changes

Tests NVC-001 for safety in adults with LMNA-related dilated cardiomyopathy.

Key facts

Who runs it
Nuevocor Pte. Ltd.
Where
Ann Arbor, Birmingham, Boston, Cincinnati, Columbus, Houston, Los Angeles, and Rochester, United StatesSee the 8 sites
Registry title
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
Status
Recruiting
Phase
Phase 1/2
People taking part
21 people, planned
Started
16 Jun 2026
Expected to end
Mar 2030
Type of study
Interventional, 3 groups
Treatments tested
  • NVC-001 - Low Dose
  • NVC-001 - Intermediate Dose
  • NVC-001 - High Dose
Record updated
7 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with dilated cardiomyopathy (an enlarged, weak heart) caused by a change in the LMNA gene. It tests the safety of a single dose of the gene therapy NVC-001.

Age
18 years and older
Sex
All sexes
Disease stage
LMNA-related dilated cardiomyopathy with reduced pumping of the left heart chamber. NYHA class I, II or III (mild to moderate heart failure symptoms). LVEF (heart pumping fraction) >25% and ≤45% on heart ultrasound.
Earlier treatment
People must have an implanted defibrillator (ICD) or CRT-D device, put in more than 3 months before consent.
Biomarker or test result
A disease-causing or likely disease-causing LMNA mutation, confirmed by a CLIA-certified/CAP-accredited laboratory.

Main reasons for not taking part

  • A long-term illness that the study doctor thinks would make taking part unsafe or hard
  • Hospital stay within 3 months for heart failure or serious heart rhythm problems needing shocks
  • Need for, or past use of, a heart pump (LV assist device) or heart transplant
  • Current or expected need for long-term IV drugs to help the heart pump

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Adult ≥18 years old, able to provide informed consent
  • Clinical diagnosis of LMNA-related dilated cardiomyopathy (DCM) with LV systolic dysfunction
  • Pathogenic or likely pathogenic LMNA mutation confirmed by a CLIA-certified/CAP-accredited laboratory
  • NYHA Functional Class I, II, or III
  • LVEF >25% and ≤45% by echocardiography
  • Implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator )CRT-D) implanted >3 months prior to consent

Who cannot take part

  • Hospitalization as an inpatient for the following conditions within 3 months prior to signing the ICF: Heart failure, Persistent/refractory ventricular arrhythmia requiring external defibrillation, or multiple/recurrent cardioversion/defibrillation by ICD Indication for, or history of, LV assist device or cardiac transplantation due to end-stage cardiac dysfunction
  • Current or anticipated need for chronic IV inotropic therapy
  • Any chronic medical condition that, in the Investigator's opinion, would compromise participant safety or compliance

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Nuevocor Clinical Trial TeamNot yet recruiting
  • University of Alabama in BirminghamBirmingham, United StatesContact: Nuevocor Clinical Trial TeamNot yet recruiting
  • Brigham and Women's HospitalBoston, United StatesContact: Nuevocor Clinical Trial TeamNot yet recruiting
  • The Christ HospitalCincinnati, United StatesContact: Nuevocor Clinical Trial TeamNot yet recruiting
  • The Ohio State UniversityColumbus, United StatesContact: Nuevocor Clinical Trial TeamNot yet recruiting
  • Houston Methodist HospitalHouston, United StatesContact: Nuevocor Clinical Trial TeamTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Nuevocor Clinical Trial TeamTaking people
  • Mayo ClinicRochester, United StatesContact: Nuevocor Clinical Trial TeamTaking people

About the trial

What the trial wants to find out

This study is designed to evaluate the safety and tolerability of NVC-001 in adults with LMNA-related dilated cardiomyopathy (LMNA-DCM). The study will also assess exploratory measures of efficacy.

The 3 groups in the trial

  • SAD low doseTreatment being tested

    Single Ascending Dose (SAD): participants will receive low dose of NVC-001

    Treatment: NVC-001 - Low Dose

  • SAD medium doseTreatment being tested

    Single Ascending Dose (SAD): participants will receive medium dose of NVC-001

    Treatment: NVC-001 - Intermediate Dose

  • SAD high doseTreatment being tested

    Single Ascending Dose (SAD): participants will receive high dose of NVC-001

    Treatment: NVC-001 - High Dose

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 1/2, First-in-Human, Open-Label, Multicenter, Single-Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NVC-001, a Novel Adeno-Associated Virus (Serotype 9) Vector Expressing a Dominant Negative SUN1 Transgene, in Patients With LMNA-Related Dilated Cardiomyopathy (SUNBEAM-LMNA)
Plain-language title
Gene therapy NVC-001 for dilated cardiomyopathy caused by LMNA changesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
7 August 2026